Researchers investigate the role the BMI1 gene plays in the onset and development of Alzheimer's disease. The study reports the loss of BMI1 triggers and increased production of amyloid beta and decreases neural ability to eliminate the protein.
Researchers are developing new psychological therapies and using cutting edge techniques to help treat symptoms of psychosis in dementia.
Researchers detail the complex interaction between alpha synuclein and the prion protein PrPc.
A new method of examining blood plasma allowed researchers to identify specific chemical bonds within the blood. The new technique allowed researchers to accurately distinguish between Alzheimer's disease and Lewy body dementia, thus reducing cases of misdiagnosis.
A common misconception is that Alzheimer's disease and dementia are the same thing. Alzheimer's disease is simply one form of dementia. Researchers from Texas A&M describe how Alzheimer's and other forms of dementia impact the lives of both patients and their families, and provide new insights into minimizing the risks of developing neurodegenerative conditions.
Researchers have implicated an enzyme that appears to make both Tau and alpha synculein more toxic in Alzheimer's and Parkinson's disease. Inhibiting this enzyme has already proved helpful in treating animal models of Alzheimer's disease. The researchers report they are moving on to testing drugs that inhibit AEP in animal models of Parkinson's disease.
Researchers report dream dysfunctions and sleep disorders may be warning signs of neurodegenerative diseases up to 15 years before other symptoms appear.
A new study reveals information about life expectancy for those with Parkinson's and other synucleinopathies.
Hippocampal shrinkage may could signify people with memory problems could develop Lewy body dementia rather than Alzheimer's disease, a new study reports.
A new study reports on how the clinical profiles of Lewy body dementia differ from Alzhiemer's or Parkinson's disease.
A new model of Parkinson's disease demonstrates how abnormal alpha-synuclein proteins gradually spread from brain areas implicated in early stages of the disease to other regions of the brain.
New research aims to improve the disposal of toxic proteins in the fight against neurodegenerative diseases.
